#1 Clinical Trials Search in Europe

FOSMANOGEPIX

Fosmanogepix is an investigational antifungal medication currently being studied in several clinical trials for the treatment of serious fungal infections, including invasive candidiasis, candidemia, and infections caused by various mold species like Aspergillus, Fusarium, and Mucorales fungi. This novel drug represents a potential new treatment option for patients with life-threatening fungal infections, particularly those who may have limited treatment options due to resistant pathogens or intolerance to existing therapies. Clinical trials are evaluating both intravenous and oral formulations of fosmanogepix, which could provide flexibility in treatment approaches for these serious infections.

Table of Contents

What is Fosmanogepix?

Fosmanogepix (also known as APX001 or E210) is an investigational antifungal medication being developed to treat serious fungal infections. It is a prodrug, which means it’s an inactive compound that is converted in the body to an active drug called manogepix[1]. The prodrug format helps the medication get into your body more effectively before converting to its active form.

Fosmanogepix represents a new class of antifungal medications with a different mechanism of action than currently available treatments. This makes it particularly valuable for treating infections that are resistant to existing antifungal drugs[2].

How Fosmanogepix Works

Once in the body, fosmanogepix is converted to manogepix, which is the active drug that fights fungal infections. The clinical trials focus on measuring the concentration and behavior of manogepix in the bloodstream to understand how the medication works[1].

What makes fosmanogepix special is that it works differently from other antifungal medications. This novel mechanism of action means it may be effective against fungi that have become resistant to conventional treatments[2].

Conditions Treated with Fosmanogepix

Fosmanogepix is being investigated for treating several types of serious fungal infections:

  • Candidemia and Invasive Candidiasis: A life-threatening bloodstream infection caused by yeast called Candida[3].
  • Invasive Mold Infections: Including those caused by:
    • Aspergillus species: A common mold that can cause serious lung infections[2].
    • Rare molds such as Scedosporium species, Fusarium species, and Mucorales fungi[2].
    • Lomentospora prolificans: A rare but difficult-to-treat fungal infection[4].
    • Multidrug-resistant molds: Fungi that have developed resistance to multiple conventional antifungal medications[4].

These infections are particularly serious for people with weakened immune systems and can be life-threatening. Having new treatment options is critically important, especially for infections that don’t respond to current medications[2].

How Fosmanogepix is Administered

Fosmanogepix can be administered in two ways:

  • Intravenous (IV) infusion: The medication is given directly into a vein, typically for initial treatment or more severe infections[5].
  • Oral tablets: Patients may switch to tablets after initial IV treatment or start with tablets in less severe cases[5].

This flexibility in administration is beneficial because it allows patients to start treatment in the hospital with IV medication and potentially continue at home with oral tablets. In clinical trials, some treatment regimens involve starting with IV administration and then switching to oral tablets after a few days[3].

Current Clinical Trials

Fosmanogepix is currently being studied in several clinical trials:

  • Phase 1 trials: These early studies are examining how fosmanogepix works in the body of healthy individuals, including studies in Chinese subjects and people with various degrees of liver impairment[1][6].
  • Phase 2 trials: These are evaluating the safety and efficacy of fosmanogepix in treating invasive fungal infections caused by Aspergillus species or rare molds[2].
  • Phase 3 trials: More advanced studies comparing fosmanogepix to standard treatments:
    • For candidemia and invasive candidiasis, comparing fosmanogepix to caspofungin (IV) followed by fluconazole (oral)[3].
    • For invasive mold infections, evaluating fosmanogepix against standard care or as a treatment option when other treatments have failed[4].

In these studies, researchers are looking at important outcomes like:

  • Survival rates
  • Whether the infection is successfully treated
  • How quickly the infection clears
  • Safety information and side effects
  • How the medication behaves in the body[3][4]

Safety Profile

As with any investigational medication, understanding the safety profile is crucial. The clinical trials for fosmanogepix are collecting extensive safety data, including:

  • Treatment-emergent adverse events (side effects that appear during treatment)
  • Serious adverse events
  • Effects on laboratory tests
  • Effects on vital signs
  • Neurological examination findings
  • Heart rhythm changes on electrocardiograms (ECGs)[2][4]

Since fosmanogepix is still in clinical trials, the full safety profile is not yet established. However, the ongoing studies will help determine the most common side effects and any safety concerns that patients and healthcare providers should be aware of.

Expanded Access Program

An Expanded Access Program (EAP) has been established for fosmanogepix. This program is designed to provide the medication to patients with serious or life-threatening invasive fungal infections who have no other treatment options[5].

The EAP is specifically intended for patients who:

  • Have a proven or probable serious or life-threatening invasive fungal infection
  • Have exhausted all other treatment options
  • Cannot participate in ongoing clinical trials
  • Have infections with resistant fungal pathogens that don’t respond to available treatments[5]

This program recognizes the urgent need for new treatment options for patients with difficult-to-treat fungal infections.

Patient Considerations

If you or someone you know has a serious fungal infection, here are some important considerations regarding fosmanogepix:

  • Availability: As an investigational drug, fosmanogepix is primarily available through clinical trials or the Expanded Access Program.
  • Clinical trial participation: Participating in a clinical trial may provide access to fosmanogepix before it’s widely available. Clinical trials have specific eligibility criteria that your healthcare provider can discuss with you[3][4].
  • Treatment duration: In the clinical trials, treatment duration varies depending on the type and severity of infection. For candidemia/invasive candidiasis, treatment may last up to 6 weeks[3]. For invasive mold infections, treatment may target 84 days but can extend up to 180 days[4].
  • Special populations: Studies are investigating how fosmanogepix works in people with liver impairment to determine if dose adjustments might be needed[1].

If you have a serious fungal infection that isn’t responding to current treatments, discuss with your healthcare provider whether fosmanogepix clinical trials or the Expanded Access Program might be appropriate options for you.

Aspect Details
Drug Name Fosmanogepix (also known as APX001, E210)
Active Moiety Manogepix
Drug Classification Investigational antifungal agent
Administration Routes Intravenous (IV) infusion and oral tablet
Target Conditions – Candidemia
– Invasive candidiasis
– Invasive mold infections (Aspergillus, Fusarium, Scedosporium, Lomentospora prolificans, Mucorales fungi)
Current Trial Phases – Phase 1 (pharmacokinetics, safety in healthy volunteers and special populations)
– Phase 2 (preliminary efficacy in invasive mold infections)
– Phase 3 (comparative efficacy against standard treatments)
Comparator Drugs in Trials – Caspofungin (IV)
– Fluconazole (oral)
Special Populations Studied – Patients with hepatic impairment
– Chinese healthy volunteers
– Patients with resistant fungal infections
Treatment Duration in Trials Varies by study – from single dose to up to 180 days of treatment
Expanded Access Available for patients with serious or life-threatening invasive fungal infections who have no other treatment options

FAQ

  • What is fosmanogepix and how does it work? Fosmanogepix is an investigational antifungal medication being studied for treating serious fungal infections. It's a prodrug that converts in the body to its active form called manogepix. While the exact mechanism isn't detailed in the clinical trial information, it appears to work differently from existing antifungal medications, potentially offering an advantage against drug-resistant fungi.
  • What types of fungal infections is fosmanogepix being studied to treat? Fosmanogepix is being studied for several types of serious fungal infections, including candidemia (Candida in the bloodstream), invasive candidiasis, and invasive mold infections caused by organisms such as Aspergillus, Fusarium, Scedosporium, Lomentospora prolificans, and Mucorales fungi. These are serious, often life-threatening infections that can be difficult to treat with existing medications.
  • How is fosmanogepix administered to patients? Fosmanogepix can be administered in two forms: as an intravenous (IV) infusion directly into a vein or as an oral tablet taken by mouth. Many of the clinical trials are studying both forms, with patients often starting on IV treatment and then potentially switching to oral tablets. This flexibility could allow patients to continue treatment at home after hospital discharge.
  • What are the main clinical trials currently studying fosmanogepix? There are several clinical trials studying fosmanogepix, including: Phase 1 studies examining how the drug works in healthy volunteers and those with liver impairment; a Phase 2 study for invasive mold infections; Phase 3 studies comparing fosmanogepix to standard treatments for candidemia/invasive candidiasis and for invasive mold infections; and an expanded access program for patients with serious fungal infections who have no other treatment options.
  • What is the current status of fosmanogepix – is it approved for use? Based on the clinical trial information, fosmanogepix is still an investigational drug that has not yet received regulatory approval. It's currently being studied in various phases of clinical trials, including Phase 1, Phase 2, and Phase 3 studies. There is also an expanded access program for patients with serious fungal infections who have no other treatment options, but this doesn't represent standard approval for general use.

Ongoing Clinical Trials on FOSMANOGEPIX

  • Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium France Germany Greece Italy +2

  • Study on the Effectiveness and Safety of Fosmanogepix Compared to Caspofungin and Fluconazole for Adults with Candidemia or Invasive Candidiasis

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria France Germany Greece +2

Glossary

  • Fosmanogepix: An investigational antifungal medication (also known as APX001 or E210) that is being studied for the treatment of serious fungal infections. It's a prodrug that converts in the body to its active form, manogepix.
  • Manogepix: The active form (active moiety) of fosmanogepix that works against fungal infections after the prodrug is metabolized in the body.
  • Invasive Fungal Infections: Serious infections where fungi invade tissues or organs, often causing life-threatening illness, especially in people with weakened immune systems.
  • Candidemia: A bloodstream infection caused by Candida species (a type of yeast), which can be life-threatening if not treated properly.
  • Invasive Candidiasis: An infection where Candida yeast has spread beyond the bloodstream and into other tissues or organs of the body.
  • Invasive Mold Infections: Serious infections caused by molds (filamentous fungi) that invade tissues or organs, often difficult to treat and potentially life-threatening.
  • Aspergillus: A genus of molds that can cause serious lung infections and other invasive infections, particularly in immunocompromised patients.
  • Mucorales fungi: A group of molds that can cause a rare but serious infection called mucormycosis, which can be rapidly progressive and life-threatening.
  • Fusarium: A genus of molds that can cause serious infections in immunocompromised patients, often resistant to many antifungal treatments.
  • Scedosporium: A genus of molds that can cause serious infections and is often resistant to many available antifungal medications.
  • Lomentospora prolificans: A mold species that can cause serious infections and is often highly resistant to available antifungal treatments.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Cmax: Maximum observed concentration of a drug in the blood after administration, a key pharmacokinetic parameter.
  • AUC: Area Under the Curve, a measure of the total exposure to a drug over time, used in pharmacokinetic studies.
  • Primary therapy: The first treatment given for a disease or condition.
  • Salvage treatment: Treatment given after patients did not respond to previous treatments or could not tolerate them due to side effects.
  • Hepatic function/impairment: Refers to how well the liver is working. Hepatic impairment means reduced liver function, which can affect how drugs are processed in the body.
  • Adverse event (AE): Any undesirable experience associated with the use of a medical product in a patient. These may or may not be caused by the drug.
  • Serious adverse event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes disability, or requires intervention to prevent permanent damage.

References

  1. https://clinicaltrials.gov/study/NCT05582187
  2. https://clinicaltrials.gov/study/NCT04240886
  3. https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-fosmanogepix-compared-to-caspofungin-and-fluconazole-for-adults-with-candidemia-or-invasive-candidiasis/
  4. https://clinicaltrials.gov/study/NCT06925321
  5. https://clinicaltrials.gov/study/NCT06433128
  6. https://clinicaltrials.gov/study/NCT06961708